Viewing Study NCT05189093


Ignite Creation Date: 2025-12-25 @ 1:19 AM
Ignite Modification Date: 2025-12-29 @ 3:35 AM
Study NCT ID: NCT05189093
Status: RECRUITING
Last Update Posted: 2025-10-01
First Post: 2021-12-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module